Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma.

Details

Serval ID
serval:BIB_689CAC58A4EB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Sustained response to trametinib in an adult patient with neurofibromatosis type 1 and high-grade glioma.
Journal
Child's nervous system
Author(s)
Dion B., Sathyakumar S., Silverman J., Coltin H., Legault G., Perreault S., D'Astous M., Lessard N., Saikali S., Dion N., Lava S., Bouffet E., Jabado N., Renzi S.
ISSN
1433-0350 (Electronic)
ISSN-L
0256-7040
Publication state
Published
Issued date
04/06/2025
Peer-reviewed
Oui
Volume
41
Number
1
Pages
202
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: epublish
Abstract
We report the case of a 25-year-old female patient with neurofibromatosis type 1 who was diagnosed with a thalamic high-grade glioma (HGG). She was initially treated with a combination of radiotherapy and concurrent temozolomide (TMZ). Following 7 months of TMZ treatment, an MRI showed tumor progression. Empiric treatment with trametinib was started, which demonstrated significant regression of the lesion. She is currently alive with stable disease 4 years post-initial diagnosis.
Keywords
Humans, Female, Pyridones/therapeutic use, Adult, Neurofibromatosis 1/complications, Neurofibromatosis 1/drug therapy, Neurofibromatosis 1/diagnostic imaging, Pyrimidinones/therapeutic use, Glioma/drug therapy, Glioma/complications, Glioma/diagnostic imaging, Brain Neoplasms/drug therapy, Brain Neoplasms/complications, Brain Neoplasms/diagnostic imaging, Magnetic Resonance Imaging, Antineoplastic Agents/therapeutic use, Temozolomide, HGAP, High-grade glioma (HGG), Neurofibromatosis type 1 (NF1), Targeted therapy, Trametinib
Pubmed
Create date
07/06/2025 12:19
Last modification date
08/06/2025 7:17
Usage data